Black Rock Inc. Elevation Oncology, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 2,490,249 shares of ELEV stock, worth $896,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,490,249

Previous 171,901 1348.65%

Holding current value

$896,489

Previous $881,000 663.11%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.35 - $5.17 $5.45 Million - $12 Million	2,318,348 Added 1348.65%	2,490,249 $6.72 Million
Q1 2024 May 10, 2024	BUY	$0.59 - $5.13 $53,822 - $467,984	91,225 Added 113.08%	171,901 $881,000
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.69 $16,434 - $29,841	43,249 Added 115.56%	80,676 $43,000
Q3 2023 Nov 13, 2023	SELL	$0.65 - $1.56 $2,585 - $6,205	-3,978 Reduced 9.61%	37,427 $24,000
Q2 2023 Aug 11, 2023	BUY	$1.4 - $5.06 $12,115 - $43,789	8,654 Added 26.42%	41,405 $62,000
Q1 2023 May 12, 2023	SELL	$0.75 - $2.55 $3,593 - $12,217	-4,791 Reduced 12.76%	32,751 $62,000
Q4 2022 Feb 13, 2023	BUY	$0.89 - $1.19 $601 - $804	676 Added 1.83%	37,542 $35,000
Q3 2022 Nov 14, 2022	SELL	$1.03 - $1.53 $870 - $1,292	-845 Reduced 2.24%	36,866 $42,000
Q2 2022 Aug 12, 2022	SELL	$1.26 - $3.94 $638 - $1,997	-507 Reduced 1.33%	37,711 $52,000
Q1 2022 May 12, 2022	BUY	$2.34 - $6.41 $32,610 - $89,329	13,936 Added 57.39%	38,218 $96,000
Q4 2021 Feb 10, 2022	BUY	$4.15 - $8.86 $1,846 - $3,942	445 Added 1.87%	24,282 $146,000
Q3 2021 Nov 09, 2021	BUY	$7.66 - $16.11 $182,591 - $384,014	23,837 New	23,837 $186,000

Others Institutions Holding ELEV

# of Institutions

Shares Held

32M

Call Options Held

50K

Put Options Held

View Full List

About Elevation Oncology, Inc.

Ticker ELEV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,300,900
Market Cap $8.39M
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...

More about ELEV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account